Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder

Journal of Clinical Psychopharmacology

Volumn 17, Issue 1, 1997, Pages 15-21

  Baker, Brian ^a,c   Dorian, Paul ^b   Sandor, Paul ^a   Shapiro, Colin ^a   Schell, Cathy ^a   Mitchell, Janet ^b   Irvine, M Jane ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOXEPIN; FLUOXETINE;

ADULT; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAPHY; FEMALE; HEART CONDUCTION; HEART RATE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPOLARIZATION; VERTIGO; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DOXEPIN; ELECTROCARDIOGRAPHY; FEMALE; FLUOXETINE; HEART CONDUCTION SYSTEM; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; PERSONALITY INVENTORY; SIGNAL PROCESSING, COMPUTER-ASSISTED;

EID: 0031022154     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199702000-00004     Document Type: Article

References (56)

1. Roose SP, Glassman AH, Giardina EG, Walsh BT, Woodring S, Bigger JT. Tricyclic antidepressants in depressed patients with cardiac conduction disease. Arch Gen Psychiatry 1987;44:237-75.
2. Schneider LS, Cooper TB, Severson JA, Zemplenyi T, Sloane RB. Electrocardiographic changes with nortriptyline and hydroxynortriptyline in elderly depressed out-patients. J Clin Psychopharmacol 1988;8:402-8.
3. Glassman AH, Preud'homme XA. Review of the cardiovascular effects of heterocyclic antidepressants. J Clin Psychiatry 1993; 54[suppl 2]:16-22.
4. Rudorfer MV, Manji HK, Potter WZ. Comparative tolerability proflies of being newer versus older antidepressants. Drug Saf 1994; 10:18-46.
5. Pitts NE. The clinical evaluation of doxepin - a new psychotherapeutic agent. Psychosomatics 1969;10:164-71.
6. Tobis JM, Aronow WS. Cardiotoxicity of amitriptyline and doxepin. J Clin Pharm Ther 1981;29:359-64.
7. Luchins DJ. Review of clinical and animal studies comparing the cardiovascular effects of doxepin and other tricyclic antidepressants. Am J Psychiatry 1983;140:1006-9.
8. Roose CP, Daleck GW, Glassman AH, Woodring S, Walsh BT, Giardina E. Is doxepin a safer tricyclic for the heart? J Clin Psychiatry 1991;52:338-41.
9. Gram LF. Fluoxetine. N Engl J Med 1994;331:1354-61.
10. Cowley G, Springen K, Leonard E. The promise of Prozac. Newsweek (1990, March 26) 39-41.
11. Fisch C. Effect of fluoxetine on electrocardiogram. J Clin Psychiatry 1995;46[sec. 2]:42-4.
12. Wouters W, Deiman W. Acute cardiac effects of fluvoxamine and other antidepressants in conscious rabbits. Arch Int Pharmacodyn Ther 1983;263:197-207.
13. Cain CR, Hamilton CC, Norton J, Petersen EN, Poyser R, Thormahlen D. Relative lack of cardiotoxicity of paroxetine in animal models. Acta Psychiatr Scand 1989 80[suppl 350]:27-30.
14. Laird LK, Lydiard RB, Morton W, Steele T, Kellner C, Thompson N, Ballenger J. Cardiovascular effects of imipramine, fluvoxamine and placebo in depressed out-patients. J Clin Psychiatry 1993;54:224-8.
15. Roose CP, Glassman AH. Cardiovascular effects of new antidepressants. Symposium No. 16B. American Psychiatric Association Meeting, San Francisco, May 1994.
16. Kuhs H, Rudolf GA. Cardiovascular effects of paroxetine. Psychopharmacology 1990;102:379-82.
17. Freedman R, Karagounis L, Steinberg J. Effects of sotalol on the signal-averaged electrocardiogram in patients with sustained ventricular tachycardia; relation to suppression on inducibility and to changes in tachycardia cycle links. J Am Coll Cardiol 1992;20:1213-9.
18. Freedman R, Steinberg J. Selective prolongation of QRS late potentials by sodium channel blocking anti-arrhythmic drugs; relation to slowing of ventricular tachycardia. Electrophysiologic study versus electrocardiographic monitoring trial (ESVEM) investigators. J Am Coll Cardiol 1991;17:1017-25.
19. Kechar DL. Signal averaged electrocardiogram in the assessment of cardiac arrhythmias. In: Podrid PJ, Kowey P, eds. Cardiac arrhythmia: mechanisms, diagnosis, and management. Baltimore: Williams & Wilkins, 1995:247-56.
20. Spitzer R, Williams Y. Instruction manual for the structured clinical interview for DSM III (SCID). New York: New York Biometric Research Dept., State Psychiatric Institute, 1985.
21. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
22. Steinberg J, Hochman J, Morgan C, et al. Effects of thrombolytic therapy administered 6 to 24 hours after myocardial infarction on the signal ECG. Results of a multicentre randomized trial. LATE Ancillary Study Investigators. LATE assessment of thrombolytic efficient efficacy. Circulation 1994;90:746-52.
23. Statters T, Malik M, Ward D, Camm AJ. QT dispersion; problems of methodology, clinical significance. J Cardiovasc Electrophysiol 1994;5:672-85.
24. Montgomery S, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
25. Beck A, Steer R. Depression inventory manual. Toronto: Psychological Corporation, Harcourt Brace, 1987.
26. Derogatis L. The SCL90R administration, scoring and procedures manual II. Towson, MD: Clinical Psychometric Research, 1983.
27. Pinder RM, Brogden RN, Speight TM, Avery GS. Doxepin up-to-date; a review of its pharmacological properties and therapeutic efficacy with particular reference to depression. Drugs 1977;13: 161-218.
28. Cooper GL. The safety of fluoxetine - an update. Br J Psychiatry 1988;153[suppl 3]:77-86.
29. Dixon W, Engelman L, Hill M, Gennrisch R, eds. BMDP statistical software manual. Berkeley, CA: University of California Press, 1988.
30. Brennan FJ. Electrophysiologic effects of imipramine and doxepin on normal and depressed cardiac Purkinje fibres. Am J Cardiol 1980;6:599-606.
31. Veith R, Friedl R, Bloom V, Bielski R. Electrocardiographic changes and plasma desipramine levels during treatment of depression. Clin Pharmacol Ther 1980;27:796-802.
32. Giardina E, Bigger JT, Glassman A, Berel J, Kantor S. The electrocardiographic and antiarrhythmic effects of imipramine HCl at therapeutic plasma concentrations. Circulation 1979;60:1045-52.
33. Vohra J, Burrows J, Sloman J. Assessment of cardio-vascular side effects of therapeutic doses of tricyclic antidepressant drugs. Aust N Z J Med 1975;5:7-11.
34. Burrows J, Vohra J, Dumovic B, et al. Tricyclic antidepressant drugs and cardiac conduction. Prog Neuropsychopharmacol 1977;1:329-34.
35. Weld F, Bigger J. Electrophysiological effects of imipramine on ovine cardiac Purkinje and ventricular muscle fibres. Circ Res 1980;46:167-75.
36. Boehnert M, Lovejoy F. Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic anti-depressants. N Engl J Med 1985;313:474-9.
37. Higham P, Campbell R. QT dispersion. Br Heart J 1994;71:508-10.
38. Kuhs H, Rudolf G. Cardiovascular effects of paroxetine. Psychopharmacology 1990;102:379-82.
39. Laird L, Lydiard RB, Morton W. Cardiovascular effects of imipramine, fluvoxamine and placebo in depressed outpatients. J Clin Psychiatry 1993;54:224-8.
40. Grassi B, Gambini O, Scarone S. Severe bradycardia following fluoxetine administration: a case report in a young HIV-1 infected woman. Hum Psychopharmacol 1995;10:153-5.
41. Davis T, Veggeberg S, Hameroff S, Watts K. Sensitive and quantitative determination of plasma doxepin, desmethyl-doxepin in chronic pain patients by gas chromatography, mass spectrometry. J Chromatogr 1983;273:436-41.
42. Orsulak P. Therapeutic monitoring of antidepressant drugs: current methodologies and applications. J Clin Psychiatry 1986; 47:39-50.
43. Altamura A, Moro A, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994;26:204-14.
44. Yusuf S, Venkatesh G, Teo K. Critical review of the approaches to the prevention of sudden death. Am J Cardiol 1993;72:51F-58F.
45. Singh B. Controlling cardiac arrhythmias by lengthening repolarisation; historical overview. Am J Cardiol 1993;72:18F-24F.
46. Jackman W, Friday K, Anderson J, Allot E, Clark M, Lazzara R. The long QT syndromes; a critical review; new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988; 31:115-72.
47. Waldo A, Camm A, de Ruyter H. Preliminary mortality results from the survival with oral D-sotalol (SWORD) trial [abstract]. J Am Coll Cardiol 1995;2:15A.
48. Salata J, Jurkiewicz N, Wallace A, Stupienski R, Guinosso P, Lynch J. Cardiac electrophysiological actions on the H-1 receptor and antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res 1995;76:110-9.
49. MacMahon S, Collins R, Peto R, Costas R. Effects of prophylactic lidocaine in suspected myocardial infarction. A review of results from the randomised control trials. JAMA 1988;260: 1910-60.
50. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction; impact on 6 months' survival. JAMA 1993; 270:1819-25.
51. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18 month prognosis following myocardial infarction. Circulation 1995;91:999-1005.
52. Cardiac arrhythmia suppression trial (CAST) investigators. Preliminary report; effect of encainide, flecainide on mortality in a randomised trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12.
53. Glassman A, Roose S, Bigger TJ. The safety of tricyclic antidepressants in cardiac patients; risk benefit reconsidered. JAMA 1993;269:2674-5.
54. Feighner GP, Cohn JB. Double blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J Clin Psychiatry 1985;46:20-5.
55. Montgomery SA. Efficacy of fluoxetine as an antidepressant in the short and long term. Int Clin Psychopharmacol 1989;4[suppl 1]:113-9.
56. Roose S, Glassman A, Attia E, Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994;151:1735-9.